Pharmacia & Upjohn, Prizm Form Alliance
Pharmacia & Upjohn Inc., a Swedish-American drug maker, said it will cooperate with San Diego-based Prizm Pharmaceuticals in developing the ophthalmology drug Pantarin. The protein-based drug is mainly used to treat post-cataract opacification, a condition that appears in 30% to 50% of the 4 million patients annually who have lens-replacement operations after cataract surgery. It works by seeking out and destroying proliferating cells. Pharmacia & Upjohn has injected capital into closely held Prizm and will be responsible for clinical trials, production and worldwide marketing, while Prizm receives payments and royalties.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.